Investor webinar – Phase 1 MND Study Top-Line Results

26 February 2024 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it will hold an investor webinar for shareholders and interested parties to discuss the pending announcement of its Phase 1 MND Study Top-Line Results.

PharmAust CEO Dr Michael Thurn will present as part of the webinar, to be held at 5:30pm AEDT Tuesday 27 February 2024.

Those interested in attending the webinar are encouraged to register at the following link: https://us02web.zoom.us/webinar/register/WN_7pVv1wrsS66OYP5IAwY6Gw

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that wish to join by phone.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

Please note a replay of the webinar will be available at the above-mentioned link shortly following the conclusion of the live session.

The Board authorises this announcement.

Enquiries:

Dr Michael Thurn
Chief Executive Officer

investorenquiries@pharmaust.com

Media:

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

P +61 (8) 9202 6814
F +61 (8) 9467 6111
www.pharmaust.com

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).

PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. Top-line results are expected to be announced in Q1 CY2024. PAA anticipates starting an adaptive Phase 2/3 clinical study in H2 CY 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visit: https://investorhub.pharmaust.com/